Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Media » Press Releases
  • Media
    • Press Releases
    • Presentations

Press Releases

  • 01-Jul-2019
    SPARC Announces U.S. FDA Acceptance of NDA for TaclantisTM (Paclitaxel Injection Concentrate for Suspension) for Filing and Regulatory Review
  • 13-Mar-2019
    HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
  • 03-Dec-2018
    Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration Drug Development Program
  • 26-Nov-2018
    SPARC Announces Top-line Results of Pivotal Bioequivalence Study for Paclitaxel Injection Concentrate for Suspension
  • 14-Sep-2018
    Sun Pharma and SPARC Announce US FDA Approval of XELPROS™ to Treat Open-angle Glaucoma or Ocular Hypertension
  • 10-Sep-2018
    Audio playback of Investors Presentation
  • 04-Jul-2018
    Update on R&D Pipeline
  • 06-Oct-2017
    SPARC Provides Update on Pivotal Phase III Studies of Baclofen GRS for Treatment of Spasticity in Patients with Multiple Sclerosis
  • 14-Jun-2017
    SPARC Announces Top-line Results of Pivotal Peak Inspiratory Flow (PIF) study and Low Dose Pharmacokinetic (PK) Study for Salmeterol – Fluticasone Dry Powder Inhaler (SPARC DPI)
  • 26-Aug-2016
    Announcement - Receipt of reclassification approval from BSE

Pagination

  • First page « First
  • Previous page ‹‹
  • Page 1
  • Current page 2
  • Page 3
  • Next page ››
  • Last page Last »

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits